API | marimastat

marimastat Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Marimastat was a proposed antineoplastic drug developed by British Biotech. It acted as a broad-spectrum matrix metalloproteinase inhibitor. ^Wikipedia

Chemistry

SMILES: CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C
InChIKey: OCSMOTCMPXTDND-OUAUKWLOSA-N
Mol. Mass: 331.41
ALogP: -0.21 Partition coefficient
ChEMBL Molecule:
marimastat

More Chemistry

Pharmacology

Mechanisms of Action:
- Interstitial collagenase (Homo sapiens) ^UniProt
- Macrophage metalloelastase (Homo sapiens) ^UniProt
- 72 kDa type IV collagenase (Homo sapiens) ^UniProt
- Stromelysin-1 (Homo sapiens) ^UniProt
- Matrilysin (Homo sapiens) ^UniProt
- Matrix metalloproteinase-9 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

bb-2516 | marimastat

Organizations (10)

Research & Development (10)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Breast Neoplasms (Phase 3)

Lung Neoplasms (Phase 3)

Vascular Diseases (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 4
# of Trial Organizations: 10

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue